Literature DB >> 22983913

Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Lindsay C George1, Martin Rowe, Christopher P Fox.   

Abstract

The potent growth-transforming properties of Epstein-Barr virus (EBV) and its role in pathogenesis of a range of B cell and epithelial malignancies are well established. By contrast, the association of this B lymphotropic virus with malignancies of T and NK cell origin was entirely unexpected. Although a number of mature T and NK lymphoma subtypes have been associated with EBV, evidence for a robust viral/tumour relationship is principally limited to extranodal NK/T lymphoma (ENKTL). Despite progress in diagnosis and classification, alongside an evolving understanding of ENKTL pathobiology, EBV's contribution to lymphomagenesis remains largely unresolved. Challenges relate to the rarity of this entity, a lack of clinical and biological correlative data and scarcity of fresh tissue for molecular and functional studies. Nonetheless, recent studies on viral and cellular gene expression have permitted new avenues of investigation into ENKTL pathobiology aiming to extend our understanding of disease biology and ultimately improve clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983913     DOI: 10.1007/s11899-012-0136-z

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  93 in total

1.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

2.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

3.  Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus.

Authors:  H Nagata; A Konno; N Kimura; Y Zhang; M Kimura; A Demachi; T Sekine; K Yamamoto; N Shimizu
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

4.  Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL.

Authors:  Naoko Kanemitsu; Yasushi Isobe; Azuchi Masuda; Shuji Momose; Morihiro Higashi; Jun-ichi Tamaru; Koichi Sugimoto; Norio Komatsu
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

5.  Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations.

Authors:  L L Siu; K F Wong; J K Chan; Y L Kwong
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

6.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.

Authors:  Yoshinori Ito; Hiroshi Kimura; Yoshinobu Maeda; Chizuko Hashimoto; Fumihiro Ishida; Koji Izutsu; Noriyasu Fukushima; Yasushi Isobe; Jun Takizawa; Yuichi Hasegawa; Hajime Kobayashi; Seiichi Okamura; Hikaru Kobayashi; Motoko Yamaguchi; Junji Suzumiya; Rie Hyo; Shigeo Nakamura; Keisei Kawa; Kazuo Oshimi; Ritsuro Suzuki
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

8.  Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria.

Authors:  Marco Herling; George Z Rassidakis; Dan Jones; Annette Schmitt-Graeff; Andreas H Sarris; L Jeffrey Medeiros
Journal:  Hum Pathol       Date:  2004-04       Impact factor: 3.466

9.  Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases.

Authors:  Hiroshi Kimura; Kanae Miyake; Yohei Yamauchi; Kana Nishiyama; Seiko Iwata; Keiji Iwatsuki; Kensei Gotoh; Seiji Kojima; Yoshinori Ito; Yukihiro Nishiyama
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

10.  Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.

Authors:  Yu Zhang; Hiroshi Nagata; Tatsuro Ikeuchi; Hiroyuki Mukai; Michiko K Oyoshi; Ayako Demachi; Tomohiro Morio; Hiroshi Wakiguchi; Nobuhiro Kimura; Norio Shimizu; Kohtaro Yamamoto
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

View more
  12 in total

1.  EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT.

Authors:  C P Fox; M J Bishton; S O'Connor; S Hughes; J L Byrne; N Russell
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

2.  Clonal sequence tracking reveals TET2-mutated extranodal NK/T-cell lymphoma disseminated independent of Epstein Barr virus.

Authors:  Chang-Tsu Yuan; Tai-Chung Huang; Chi-Chen Chuang; Yi-Kuang Chuang; Jia-Huei Tsai; Jau-Yu Liau; Chung-Wu Lin; Jih-Luh Tang
Journal:  Haematologica       Date:  2019-05-16       Impact factor: 9.941

3.  Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.

Authors:  Bradley M Haverkos; Alejandro A Gru; Susan M Geyer; Anissa K Bingman; Jessica A Hemminger; Anjali Mishra; Henry K Wong; Preeti Pancholi; Aharon G Freud; Michael A Caligiuri; Robert A Baiocchi; Pierluigi Porcu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 4.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 5.  Molecular Pathogenesis of Peripheral T Cell Lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Shigeru Chiba
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 4.213

Review 6.  Host genetics of Epstein-Barr virus infection, latency and disease.

Authors:  Charlotte J Houldcroft; Paul Kellam
Journal:  Rev Med Virol       Date:  2014-11-27       Impact factor: 6.989

7.  Prognostic significance of latent membrane protein 1 expression in non-Hodgkin lymphoma: A meta-analysis.

Authors:  Xiao-Mei Li; Wen-Hua Xiao; Hui-Xia Zhao
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

8.  CD8+ T cell evasion mandates CD4+ T cell control of chronic gamma-herpesvirus infection.

Authors:  Cindy S E Tan; Clara Lawler; Philip G Stevenson
Journal:  PLoS Pathog       Date:  2017-04-10       Impact factor: 6.823

Review 9.  Viral Infection of Human Natural Killer Cells.

Authors:  Elisabeth A van Erp; Mirjam R van Kampen; Puck B van Kasteren; Jelle de Wit
Journal:  Viruses       Date:  2019-03-12       Impact factor: 5.048

Review 10.  Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.

Authors:  Madhan Jeyaraman; Sathish Muthu; Asawari Bapat; Rashmi Jain; E S Sushmitha; Arun Gulati; Talagavadi Channaiah Anudeep; Shirodkar Jaswandi Dilip; Niraj Kumar Jha; Dhruv Kumar; Kavindra Kumar Kesari; Shreesh Ojha; Sunny Dholpuria; Gaurav Gupta; Harish Dureja; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Saurabh Kumar Jha
Journal:  Heliyon       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.